Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10X Genomics, Inc. (TXG) drives innovation in life sciences through advanced single cell and spatial biology solutions. This news hub provides investors and researchers with essential updates about technological advancements, strategic partnerships, and financial developments shaping the future of biological research.
Access authoritative information on product launches, peer-reviewed study validations, and regulatory milestones. Our curated collection includes earnings reports, executive commentary, and analyses of how TXG's platforms enable breakthroughs in oncology, immunology, and neuroscience research.
Key updates cover instrument innovations, software enhancements, and collaborations with leading research organizations. Monitor progress in making high-resolution cellular analysis more accessible to academic institutions and biopharmaceutical developers worldwide.
Bookmark this page for streamlined access to verified TXG developments. Check regularly for insights into how the company continues redefining biological discovery through integrated hardware, consumables, and data analysis solutions.
10x Genomics (Nasdaq: TXG) reported Q2 2024 financial results with revenue of $153.1 million, a 4% increase year-over-year. The company began shipping Xenium Prime 5K, featuring enhanced chemistry and integrated multimodal cell segmentation. Gross margin remained flat at 68%, while operating expenses decreased by 10% to $146.0 million. The operating loss narrowed to $41.7 million from $63.4 million in the prior year period. Net loss improved to $37.9 million compared to $62.4 million last year. Cash and equivalents stood at $380.1 million as of June 30, 2024. 10x Genomics updated its full-year 2024 revenue guidance to $640-$660 million, representing 3-7% growth over 2023.
10x Genomics (Nasdaq: TXG) is supporting the TenK10K project, a large-scale study led by the Garvan Institute of Medical Research. The project aims to map 50 million human cells from 10,000 people to identify unique genomic fingerprints of autoimmune diseases, heart diseases, and cancer. The Garvan Institute has selected 10x Genomics' Chromium GEM-X products for single cell data generation, which offers increased sensitivity, throughput, data quality, and sample recovery.
The TenK10K project builds on the success of the Garvan Institute's OneK1K study and aims to develop commercial tests for various autoimmune diseases, early trials of RNA therapies, and potential treatments for cancers and long COVID. This collaboration showcases the potential of single cell analysis at a massive scale to impact disease understanding, diagnosis, treatment, and cure.
10x Genomics (Nasdaq: TXG) announced that it will release its Q2 2024 financial results on August 8, 2024, after market close. The company will hold a conference call and live webcast for investors and analysts at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, business developments, and future outlook. The financial results will be accessible on the company's website before the call. The live webcast will be available on the 'Investors' section of the website and will be archived for replay for at least 45 days.
On June 27, 2024, 10x Genomics (Nasdaq: TXG) announced that its Xenium In Situ platform was instrumental in a groundbreaking study published in the Journal of Dental Research. Led by NIH researchers and computational experts from the University of Connecticut, the study provided new insights into the cellular mechanisms of secondary palate formation. This research utilized the Chromium Single Cell products and Xenium In Situ to explore gene expression regulation in developing palates, revealing the role of Pax9 in Wnt signaling. The study shows that disrupting Wnt signals in Pax9-deficient mice affects bone formation, with potential implications for innovative cleft palate treatments.
The researchers created a custom gene expression panel to profile 350 genes at single-cell spatial resolution, revealing notable differences between wild-type and Pax9-deficient mice. The results suggest that targeting these pathways could lead to new diagnostic and therapeutic strategies for cleft palate anomalies, affecting about 1 in 700 live births globally.
10x Genomics (Nasdaq: TXG) has commenced commercial shipments of its new Xenium Prime 5K Pan-Tissue and Pathways panel. This advanced panel features a 5,000-plex gene capability, significantly enhancing plex capacity while maintaining top-tier per-gene sensitivity, specificity, and spatial fidelity. It also integrates multimodal cell segmentation, offering industry-leading speed and throughput. Optimized for comprehensive profiling of cell types, states, and signaling pathways across various tissues and diseases, the Xenium Prime 5K assay allows for rapid analysis of up to 472 mm² of tissue in under six days. Customizable with up to 100 additional genes, the assay is compatible with fresh frozen and FFPE samples, providing an easy, tissue-agnostic workflow. A webinar to introduce the product is scheduled for June 25, 2024.
10x Genomics announced the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel, significantly enhancing single-cell and spatial biology research. The new panel boasts a tenfold increase in plex capacity, improved per-gene sensitivity, specificity, and spatial fidelity. Key features include rapid turnaround time, customizable options, and the capability to analyze extensive tissue areas efficiently. Optimized for human and mouse species, the panel is now available for preorder, with shipments expected next month. This innovation aims to advance the exploration of molecular pathways, biomarkers, and cell interactions in various diseases.
10x Genomics, a leader in single cell and spatial biology, will be presenting at the BofA Securities 2024 Healthcare Conference. The company's management team will participate in a fireside chat on May 14 at 4:20 p.m. Pacific Time. Interested parties can access a live webcast of the event on the company's website.
Curio Bioscience reported a favorable decision from the European Unified Patent Court (UPC) regarding a patent infringement claim by 10x Genomics. The court found that Curio Seeker does not infringe on the main claim asserted by 10x Genomics and ordered Curio Bioscience not to offer any violating products in certain countries. Curio Bioscience expects no impact on its commercial business due to this ruling.
10x Genomics, Inc. reported $141.0 million in revenue for the first quarter of 2024, a 5% increase from the same period in 2023. The company introduced four major new products, including Visium HD Spatial Gene Expression and two new Chromium products powered by GEM-X. Despite revenue growth, gross margin decreased to 66% due to product mix changes. Operating expenses rose by 3% to $154.4 million, driven by higher legal expenses and facility costs. The company saw an operating loss of $61.5 million and a net loss of $59.9 million for the quarter. 10x Genomics is maintaining its full-year 2024 revenue guidance of $670 million to $690 million, anticipating 8% to 12% growth over 2023.